The loss of Alnylam Pharmaceuticals under GAAP for 9 months of 2020 amounted to $614.741 million, an increase of 0.8% compared to $609.931 million in the previous year. Revenue increased 2.2 times to $329.291 million, compared to $148.069 million a year earlier.
The loss of Alnylam Pharmaceuticals under GAAP for 9 months of 2020 amounted to $614.741 million, an increase of 0.8% compared to $609.931 million in the previous year. Revenue increased 2.2 times to $329.291 million, compared to $148.069 million a year earlier. 
investors.alnylam.com
English (US) 